News

BioPharma Services has successfully completed 3 inspections this month by the US FDA, with concurrent audits at both research centers in Toronto, Canada, and Columbia, Missouri. Over…
Read More...

Bluebee and MediSapiens enters a partnership to provide customers with tailored end-to-end analytical solutions for Next Generation Sequencing (NGS) data. Sequencing technology is…
Read More...

Compugen Ltd board of directors has appointed Michal Preminger (PhD, MBA, Executive Director at Harvard University Office of Technology Development's Harvard Medical School site) as…
Read More...

Recipharm has appointed  Shabbir Mostafa as Director, Business Management UK & Ireland with responsibility for supporting customers in the UK & Ireland and to driving up sales.…
Read More...

Avista Pharma Solutions announced that Minneapolis Medical Research Foundation (MMRF) has selected Avista Pharma to manufacture an opioid-derived small molecule. The research is funded…
Read More...

Hovione announced that it will soon initiate recruitment for its Phase 1 clinical trial of HY02. This first in human study is a double-blinded, randomized trial, which will include…
Read More...

Lysogene has completed the enrollment in its “Sanfilippo A Multi-national Observational Study” (SAMOS). Sanfilippo A is also known as Mucopolysaccharidosis Type IIIA (MPS IIIA).…
Read More...

Lysogene and Brammer Bio has entered into manufacturing agreement. Brammer Bio will produce an AAVrh10-based gene therapy, LYS-GM101 for clinical testing of the therapeutic candidate in…
Read More...

US Patent and Trade Office (USPTO) has issued Notice of Allowance to Neurana Pharmaceuticals for two new tolperisone patents, including a second Composition of Matter patent for a novel…
Read More...

US FDA has granted Orphan Drug Designation (ODD) for Abeona’s EB-101 gene therapy program for patients with dystrophic epidermolysis bullosa (DEB), including recessive dystrophic…
Read More...

Optibrium has entered into a collaboration with Imperial College London for developing new treatments for neglected diseases as part of a collaborative project with DNDi (Drugs for…
Read More...

The US FDA Oncologic Drugs Advisory Committee (ODAC) recommended the approval of the Pizer’s proposed epoetin alfa biosimilar across all indications. The Committee’s favorable…
Read More...

X4 Pharmaceuticals announced dosing of the first patient in the Phase 2 portion of the ongoing Phase 1/2 study evaluating X4P-001, the CXCR4 inhibitor, in combination with Inlyta…
Read More...

The US FDA accepted Bristol-Myers Squibb supplemental BLA to extend the use of Opdivo (nivolumab) to patients with hepatocellular carcinoma (HCC) after prior sorafenib therapy. The FDA…
Read More...

Constellation Pharmaceuticals has appointed Jigar Raythatha as president and CEO. He will lead the company focused on harnessing its deep scientific expertise in cancer epigenetics, to…
Read More...

Optum announced that they will collaborate with Merck to explore value-based and pay-for-performance models, known as Outcomes-Based Risk Sharing Agreements (OBRSAs), and their…
Read More...

PharmaMar has signed agreement with Eczacibasi Group to commercialize the marine-derived anticancer drug Aplidin (plitidepsin) in Turkey. Aplidin is PharmaMar´s second most advanced…
Read More...

The U.S. Patent and Trademark Office has issued a Notice of Allowance in favour of Ammonett Pharma for Patent Application No: 15/271,542, entitled “DETECTING AND TREATING GROWTH HORMONE…
Read More...

Akebia Therapeutics has appointed Rita Jain, M.D. as Senior VP and CMO. She will be responsible for leading the clinical development of the Company's HIF pipeline, including the global…
Read More...

miRagen Therapeutics announced that  MRG-106 has received orphan medicinal product designation from European Commission (EC) for the treatment of cutaneous T-cell lymphoma (CTCL). CTCL…
Read More...